Clinical role of the long non‑coding RNA, EGFR‑AS1, in patients with cancer: A systematic review and meta‑analysis

Abstract

The novel long non-coding RNA, EGFR-AS1, is expressed in various types of solid tumour, and its oncogenic role has been fully identified. In the present study, several articles were screened following an electronic search of the PubMed database. In total, 8 studies were included in the present systematic review. For each analysis indicator risk ratios (RRs) with 95% confidence intervals (CIs) or hazard ratios (HRs) with standard errors and 95% CIs were estimated using Review Manager 5.3. The pooled RR of high EGFR-AS1 expression among patients with or without vascular invasion was 1.81 with a 95% CI of 1.22–2.69; the pooled HR of high EGFR-AS1 expression for patient overall survival rate was 1.74 with a 95% CI of 1.39–2.18. Therefore, EGFR-AS1 was identified as an oncogene and the upregulated EGFR-AS1 expression was significantly associated with advanced tumour progression and poor prognosis.